[1. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99: 1441-54.10.1093/jnci/djm13517895480]Search in Google Scholar
[2. Kyle AH, Minchinton AI. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother Pharmacol. 1999;43:213-20.10.1007/s0028000508869923551]Search in Google Scholar
[3. Rischin D, Peters L, Fisher R. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol. 2005;23:79-87.10.1200/JCO.2005.01.07215625362]Search in Google Scholar
[4. Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: Comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys. 2007;69:560-71.10.1016/j.ijrobp.2007.05.04917869669]Search in Google Scholar
[5. Marcu L, Olver I. Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol. 2006;1:71-9.10.2174/15748840677526819218666379]Search in Google Scholar
[6. Rischin D, Peters LJ, O’Sullivan B. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28:2989-95.10.1200/JCO.2009.27.444920479425]Search in Google Scholar
[7. Di Silvestro PA, Ali S, Craighead PS. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol. 2014;32:458-64.10.1200/JCO.2013.51.4265391233024395863]Search in Google Scholar
[8. Chen HHW, Kuo MT. Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy. Metal-Based Drugs. 2010;2010:430939.]Search in Google Scholar
[9. Ozkan TA, Aydin U, Ay D, Cebeci IOO. Cisplatin and bleomycininduced acute peripheral-vascular stenosis in patient with testicular cancer. Urology Annals. 2016;8:483-5.10.4103/0974-7796.192096510015928057998]Search in Google Scholar
[10. Qian X, Ma C, Hoffmann TK, Kaufmann AM, Albers AE. Taxanecisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety. SpringerPlus. 2015;4:208.10.1186/s40064-015-0988-5442282725977896]Search in Google Scholar
[11. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78.10.1016/j.ejphar.2014.07.025414668425058905]Search in Google Scholar
[12. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin Nephrotoxicity. Toxins. 2010;2:2490-518.10.3390/toxins2112490]Search in Google Scholar
[13. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin. Nephrol. 2003;23:460-4.]Search in Google Scholar
[14. Guise CP, Mowday AM, Ashoorzadeh A. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chinese Journal of Cancer. 2014;33(2):80-6.10.5732/cjc.012.10285]Search in Google Scholar
[15. Rades D, Seidl D, Janssen S, Strojan P, Karner K, Bajrovic A, Hakim SG. Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. European Archives of Oto-Rhino-Laryngology. 2017;1:1-7.10.1007/s00405-016-4326-5]Search in Google Scholar
[16. Rabik C, Fishel M, Holleran J, Kasza K, Kelley M, Egorin M, Dolan M. Enhancement of cisplatin cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J. Pharmacol. Exp. Ther. 2008;327:442-52.]Search in Google Scholar
[17. Santos NA, Catao CS, Martins NM, Curti C, Bianchi ML, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 2007;81(7): 495-504.10.1007/s00204-006-0173-2]Search in Google Scholar
[18. Kadikoylu G, Bolaman Z, Demir S, Balkaya M, Akalin N, Enli Y. The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol. 2004;23:29-34.10.1191/0960327104ht413oa]Search in Google Scholar
[19. Delahoussaye YM, Evans JW, Brown JM. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol. 2001;62(9):1201-9.10.1016/S0006-2952(01)00784-5]Search in Google Scholar